4-HO-MET

4-HO-MET (4-hydroxy-N-methyl-N-ethyltryptamine; metocin) is a substituted tryptamine and is covered by the current NPSV generic Tryptamin-Verbindungen definition. It is not asserted as individually named in the current Suchtgiftverordnung schedules. The NPSG regime principally criminalizes benefit-intended manufacture/import/export/transfer/supply with intended psychoactive use and allows seizure/forfeiture; the statutory medicines and Suchtmittelgesetz exclusions and lawful-use exceptions remain applicable. The canonical status is analog_covered because coverage is via a generic NPS/NPSV structural class, not an individual narcotics-schedule listing.

4-HO-MET is expressly named as 4-hydroxy-N-methyl-N-ethyltryptamine (Metocin) in Bulgaria's Appendix No. 1 List I. List I is the high-risk category prohibited for human and veterinary application. Article 30 of the Narcotic Substances and Precursors Control Act prohibits ordinary handling and possession of List I plants, substances and preparations; Article 31 preserves only limited quantities provided under the Act for medical, scientific, laboratory-research or educational purposes. The latest State Gazette amendment checked (No. 73/2026) does not alter the named 4-HO-MET row.

4-HO-MET (metocin; 4-hydroxy-N-ethyl-N-methyltryptamine) matches Hungary's current generic Annex 3 tryptamine definition: its tryptamine nitrogen bears ethyl and methyl groups, and its indole ring bears hydroxy at position 4. The current administrative regime requires an activity permit for listed operations and allows use only for research or industrial purposes (subject to the cited statutory exception). The primary sources support generic NPS structural coverage, not an individually named Annex 1/2 narcotic or psychotropic listing; no broader criminal-penalty conclusion is asserted here.

4-HO-MET is supported by Lithuania's current generic tryptamine-derivative entry in List I, not by an exact-name listing. Its 4-hydroxy indol-3-ylethanamine core and N-ethyl/N-methyl amino substitution fall within item 137. The current Control Act makes the same control regime automatic for derivatives in a listed group and prohibits List I lawful circulation except narrow registered-medicine, research, official-function and accredited-laboratory exceptions. Canonical status is therefore prohibited.

Portugal expressly lists 4-HO-MET (4-hidroxi-N-metil-N-etiltriptamina) as a new psychoactive substance. The Decreto-Lei 54/2013 framework prohibits ordinary production, import, export, advertising, distribution, sale, possession and making available, subject to duly authorized industrial or pharmaceutical purposes. Article 10(2) separately applies the Law 30/2000 personal-use regime with necessary adaptations to detention for mere own consumption; Lei 55/2023 clarifies the ten-day amount as an indicium and the administrative/referral consequences when exclusive own use is proved. The result is normalized to restricted_other because this is an expressly listed NPS under a distinct administrative prohibition regime, not a named Decreto-Lei 15/93 narcotics-table entry; the sources do not support treating every personal-use circumstance as an independently criminal possession offense.

4-HO-MET is expressly named in Sweden's current Annex 1 narcotics schedule under Hallucinogener, and section 2 of the Narcotics Control Ordinance makes Annex 1 substances narcotics under the Narcotic Drugs Penal Law. The Narcotic Drugs Control Act restricts possession and other ordinary handling to enumerated authorized purposes, while the Penal Law criminalizes unauthorized possession, use, and other handling. This supports prohibited rather than unscheduled or merely analogue-covered status; the cited provisions preserve statutory permit and purpose-based exceptions.

The exact identity is 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET; metocin), not 4-AcO-MET. The current federal Criminal Code Regulations expressly list 4-AcO-MET, and the Criminal Code analogue provision specifies replacement of acyloxy with hydroxy as one listed structural-modification route; on that statutory text, 4-HO-MET is analog_covered as a Commonwealth controlled drug. The Poisons Standard separately lists psilocin and other named tryptamines but no exact 4-HO-MET name; its derivative guidance requires a balanced case-specific assessment, so this result does not call 4-HO-MET an express Schedule 9 entry. The current Customs compilation likewise does not expressly list 4-HO-MET in Schedule 4; regulation 5’s import prohibition applies to a Customs-defined drug, so no independent exact-name Customs classification is asserted here. Queensland independently and expressly lists 4-HO-MET in Schedule 2 and criminalizes unlawful possession. Australian State and Territory implementation can differ, and the federal analogue conclusion remains dependent on establishing the sample’s identity and applying the statutory elements; this is not a blanket claim that every non-Queensland state uses the same schedule wording.

4-HO-MET (metocin; 4-hydroxy-N-ethyl-N-methyltryptamine) is covered by Belgium's generic Annex IVA item 5 tryptamine structure: the terminal N-ethyl and N-methyl groups satisfy R1/R2, the indole-4-OH satisfies R3, and the indole N-H satisfies R4. The decree's authorization regime therefore makes import, export, transport, manufacture, possession, sale, supply, delivery and acquisition prohibited absent the applicable prior authorization, which is personal and limited to scientific or medical purposes. AFMPS warns that its consolidated PDF and indicative list are non-official/non-limitative; the Belgian Official Journal annexes and amendments control. The June 2026 Annex IVA amendment concerns only the synthetic-cannabinoid table and does not alter item 5.

For the identified pure compound, current Canadian federal sources support an unscheduled/not-controlled CDSA result: Health Canada expressly places 4-HO-MET in its NPS material whose definition says NPS are not controlled under the CDSA, and the current schedules list specific tryptamines (DET, DMT, psilocin, psilocybin and etryptamine) rather than a generic tryptamine class. The result does not legalize mislabeled or adulterated products, resolve other federal or provincial laws, or replace Health Canada's substance-status confirmation for a particular sample; analogue/derivative analysis remains tied to the applicable schedule heading.

Japan's current primary MHLW sources support canonicalStatus prohibited. 4-HO-MET is expressly listed as a designated drug, including its salts, in both the current MHLW list and consolidated designated-drug ordinance. Under PMD Act Article 76-4, ordinary recreational manufacture, import, sale, transfer, possession, purchase, receipt and use are prohibited outside legally defined medical or other permitted uses. The current MHLW narcotic designation decree/list was separately inspected; no exact 4-HO-MET row was found, so this result relies on the explicit designated-drug classification rather than treating 4-HO-MET as a named narcotic.

4-HO-MET is expressly named in Poland's current psychotropic-substance schedule as Group I-P item 47, not merely covered as an unlisted new psychoactive substance. Group I-P substances may be used only for research under Article 33(2), while possession, unlawful manufacture and unlawful market placement are criminalized under Articles 53, 56 and 62. The schedule's concluding clause includes possible salts and stereoisomers unless expressly excluded. Article 62a is a discretionary procedural discontinuance rule for insignificant own-use amounts, not a legalization or possession exemption.

4-HO-MET is expressly listed in Slovakia's current risk-substances list as item 14, under the Slovak term riziková látka. It is not individually named in the current Annex 1 narcotic/psychotropic schedule, which separately lists compounds such as DET, DMT, Etryptamín and 5-MeO-DALT. The Act's § 3(4) expressly excludes preparations containing risk substances from §§ 19–22 and 28; the fetched primary sources do not establish an unqualified criminal possession ban for pure 4-HO-MET. Canonical status is therefore restricted_other, not prohibited or unscheduled.

4-HO-MET is expressly named in the current binding Swiss Annex 6 Verzeichnis e schedule as a raw material/product with presumed narcotic-like effect. This is a controlled-products category: Article 7 requires EDI authorization for the listed activities and Article 20(1)(c) penalizes those activities without authorization, but the checked sources do not establish an unqualified blanket possession prohibition for Verzeichnis e entries. The appropriate canonical status is restricted_other rather than prohibited; applicable statutory authorizations and conduct-specific exceptions must be considered.